Clarus CorporationNASDAQ: CLAR

Claris Bio to Participate in Upcoming Investor Conferences

· Issued by Clarus Corporation via GlobeNewswire

Summary by 6ix AI

Claris Biotherapeutics, Inc., a late-stage biopharmaceutical company developing treatments for sight-threatening eye conditions, said its management will participate in the Wells Fargo 21st Annual Healthcare Conference and the Bank of America Healthcare Trailblazers Private Company Showcase Conference.

Key details

  • Wells Fargo 21st Annual Healthcare Conference: fireside chat and one-on-one meetings on Thursday, September 10, 2026, 12:45-1:20 p.m. EDT, in Boston, MA, with Stephen Brady, CEO and President of Claris Bio.
  • Bank of America Healthcare Trailblazers Private Company Showcase Conference: one-on-one meetings on Thursday, September 24, 2026, in Boston, MA.

6ix AI wrote this summary from the release below and checked it against the release.

JERSEY CITY, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Claris Biotherapeutics, Inc., a late-stage biopharmaceutical company dedicated to advancing transformative therapies for sight-threatening conditions where limited or no treatment options exist, today announced that its management will participate in the following investor conferences:

Wells Fargo 21st Annual Healthcare Conference

  • Format: Fireside chat and one-on-one meetings

  • Date/Time: Thursday, September 10, 2026, 12:45-1:20 p.m. EDT

  • Location: Boston, MA

  • Participant: Stephen Brady, CEO and President of Claris Bio

Bank of America Healthcare Trailblazers Private Company Showcase Conference

  • Format: One-on-one meetings

  • Date: Thursday, September 24, 2026

  • Location: Boston, MA

About Claris Bio
Claris Biotherapeutics is a late-stage biopharmaceutical company dedicated to advancing transformative therapies for sight-threatening conditions where no or limited treatment options exist. Backed by a Series B financing from a premier syndicate of life sciences investors and financed through pivotal development, Claris is advancing its lead therapeutic candidate, CSB-001 (oremepermin alfa ophthalmic solution), for limbal stem cell deficiency (LSCD), a blinding disease of the ocular surface with no approved pharmacologic treatment. The company intends to initiate pivotal studies in the first half of 2027, informed by WAYFINDER, the company's ongoing non-interventional natural history study in LSCD. If successful, CSB-001 would be the first pharmacologic treatment for LSCD, offering a reliable, accessible, and scalable non-surgical option that moves medical management beyond today's palliative care toward meaningful, lasting improvements in vision and ocular surface health. Foundational intellectual property for Claris was based on the scientific work of Drs. Reza Dana, MD, MSc, MPH, and Sunil Chauhan, DVM, PhD, both from Massachusetts Eye and Ear and the Harvard Medical School Department of Ophthalmology. To learn more, visit www.clarisbio.com.

Media Contact
Jordyn Temperato
LifeSci Communications
[email protected]

Clarus Corporation on 6ix

Earlier from Clarus

Later from Clarus

All Clarus news releases